Pain in arthritis

European Journal of Pain Supplements

Volumn 3, Issue 2, 2009, Pages 123-127

  Caporali, Roberto ^a   Cavagna, Lorenzo ^a   Montecucco, Carlomaurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Early arthritis; Early rheumatoid arthritis; Pain; Rheumatoid arthritis; Undifferentiated polyarthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHRONIC ARTHRITIS; DISTRESS SYNDROME; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; INFLAMMATION; MENTAL DISEASE; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; WEATHER;

EID: 70350782326     PISSN: 17543207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eujps.2009.07.009     Document Type: Article

References (77)

1. Alamanos Y., Voulgari P.V., and Drosos A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American college of rheumatology criteria: a systematic review. Semin Arthritis Rheum 36 (2006) 182-188
2. Albani G., Ravaglia S., Cavagna L., Caporali R., Montecucco C., and Mauro A. Clinical and electrophysiological evaluation of peripheral neuropathy in rheumatoid arthritis. J Peripher Nerv Syst 11 (2006) 174-175
3. Aletaha D., Nell V.P., Stamm T., Uffmann M., Pflugbeil S., Machold K., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7 (2005) R796-R806
4. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
5. Backman C.L. Arthritis and pain. Psychosocial aspects in the management of arthritis pain. Arthritis Res Ther 8 (2006) 221
6. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American college of rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 2008; September 9 [Epub ahead of print].
7. Benucci M., Cammelli E., Manfredi M., Saviola G., Baiardi P., Mannoni A., and Associazione Medici-Scandicci. Early rheumatoid arthritis in Italy: study of incidence based on a two-level strategy in a sub-area of Florence (Scandicci-Le Signe). Rheumatol Int 28 (2008) 777-781
8. Bijlsma J.W., Hoes J.N., Van Everdingen A.A., Verstappen S.M., and Jacobs J.W. Are glucocorticoids DMARDs?. Ann N Y Acad Sci 1069 (2006) 268-274
9. Bingham B., Ajit S.K., Blake D.R., and Samad T.A. The molecular basis of pain and its clinical implications in rheumatology. Nat Clin Pract Rheumatol 5 (2009) 28-37
10. Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009; February 10 [Epub ahead of print].
11. Carbonell J., Cobo T., Balsa A., Descalzo M.A., Carmona L., and SERAP Study Group. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology 47 (2008) 1088-1092
12. Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health condition among adults - United States, 1999. MMWR Morb Mortal Wkly Rep 50 (2001) 120-125
13. Cimmino M.A., Parisi M., Moggiana G., Mela G.S., and Accardo S. Prevalence of rheumatoid arthritis in Italy: the Chiavari study. Ann Rheum Dis 57 (1998) 315-318
14. Coady D.A., Armitage C., and Wright D. Rheumatoid arthritis patients' experiences of night pain. J Clin Rheumatol 13 (2007) 66-69
15. Combe B., Landewe R., Lukas C., Bolosiu H.D., Breedveld F., Dougados M., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 66 (2007) 34-45
16. Cutolo M., and Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev 7 (2008) 223-228
17. Davis M.C., Zautra A.J., Younger J., Motivala S.J., Attrep J., and Irwin M.R. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 22 (2008) 24-32
18. Dick P.J., Sherman W.R., Hallcher L.M., Service F.J., O'Brien P.C., Grina L.A., et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 8 (1980) 590-596
19. Dixon N.G., and Symmons D.P.M. Does early rheumatoid arthritis exist?. Best Pract Res Clin Rheumatol 19 (2005) 37-54
20. Drane D., Berry G., Bieri D., Mcfarlane A.C., and Brooks P. The association between external weather conditions and pain and stiffness in women with rheumatoid arthritis. J Rheumatol 24 (1997) 1309-1316
21. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol 66 Suppl. (2002) 3-8
22. Emery P., and Symmons D.P. What is early rheumatoid arthritis?: definition and diagnosis. Baillieres Clin Rheumatol 11 (1997) 13-26
23. Emery P., Breedveld F.C., Dougados M., Kalden J.R., Schiff M.H., and Smolen J.S. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61 (2002) 290-297
24. Fam A.G., Gordon D.A., Sarkozi J., Blair G.R., Cooper P.W., Harth M., et al. Neurologic complications associated with gold therapy for rheumatoid arthritis. J Rheumatol 11 (1984) 700-706
25. Fautrel B., and Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 14 (2002) 121-126
26. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al., American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
27. Fitzcharles M., and Shir Y. New concepts in rheumatic pain. Rheum Dis Clin North Am 34 (2008) 267-283
28. Fleming A., Dodman S., Crown J.M., and Corbett M. Extra-articular features in early rheumatoid disease. Br Med J 1 (1976) 1241-1243
29. Flipon E., Brazier M., Clavel G., Boumier P., Gayet A., Le Loët X., et al., VErA Group. Is it possible to identify early predictors of the future cost of chronic arthritis? The VErA project. Fundam Clin Pharmacol 23 (2009) 105-113
30. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. The elaboration of the preliminary rheumatoid arthritis impact of disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2008; December 3 [Epub ahead of print].
31. Guedj D., and Weinberger A. Effect of weather conditions on rheumatic patients. Ann Rheum Dis 49 (1990) 158-159
32. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al., National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58 (2008) 15-25
33. Hochberg M.C. Early aggressive DMARD therapy: the key to slowing disease progression in rheumatoid arthritis. Scand J Rheumatol S112 (1999) 3-7
34. Huscher D, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2008; August 6 [Epub ahead of print].
35. Jansen L.M., van Schaardenburg D., van der Horst-Bruinsma I.E., and Dijkmans B.A. One year outcome of undifferentiated polyarthritis. Ann Rheum Dis 61 (2002) 700-703
36. Jones R. Manifesto for the third millennium. Patient Netw 5 (2000) 23
37. Katz W.A., and Rothenberg R. Section I: treating the patient in pain. J Clin Rheumatol 11 2 Suppl. (2005) 16-28
38. Kho L.K., and Kermode A.G. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 14 (2007) 179-181
39. Kirwan J.R. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol 26 (1999) 720-725
40. Lozeron P., Denier C., Lacroix C., and Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66 (2009) 490-497
41. MacKichan F., Wylde V., and Dieppe P. The assessment of musculoskeletal pain in the clinical setting. Rheum Dis Clin North Am 34 (2008) 311-330
42. Mancarella L., Bobbio-Pallavicini F., Ceccarelli F., Falappone P.C., Ferrante A., Malesci D., et al., GISEA group. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 34 (2007) 1670-1673
43. McDougall J.J. Arthritis and pain: neurogenic origin of joint pain. Arthritis Res Ther 8 (2006) 220-230
44. McInnes I.B., and Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7 (2007) 429-442
45. Melzack R., and Wall P.D. Evolution of pain theories. Int Anesthesiol Clin 8 (1970) 3-34
46. Mitchell K.L., and Pisetsky D.S. Early rheumatoid arthritis. Curr Opin Rheumatol 19 (2007) 278-283
47. Nawata Y., Eugui E.M., Lee S.W., and Allison A.C. IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. Ann N Y Acad Sci 557 (1989) 230-238
48. Pincus T., Yazici Y., and Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standar clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol 21 (2007) 601-628
49. Puéchal X., Said G., Hilliquin P., Coste J., Job-Deslandre C., Lacroix C., et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 38 (1995) 1618-1629
50. Quinn M.A. Are early arthritis clinics necessary?. Best Pract Res Clin Rheumatol 19 (2005) 1-17
51. Quinn M.A., Conaghan P.G., and Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. Rheumatology 40 (2001) 1211-1220
52. Redelmeier D.A., and Tversky A. On the belief that arthritis pain is related to the weather. Proc Natl Acad Sci USA 93 (1996) 2895-2896
53. Riise T., Jacobsen B.K., and Gran J.T. Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol 27 (2000) 1386-1389
54. Rintelen B., Haindl P.M., Maktari A., Nothnagl T., Hartl E., and Leeb B.F. SDAI/CDAI levels in rheumatoid arthritis patients are highly dependent on patient's pain perception and gender. Scand J Rheumatol 37 (2008) 410-413
55. Rojas-Vargas M., Muñoz-Gomariz E., Escudero A., Font P., Zarco P., Almodovar R., et al., Registro Español de Espondiloartritis de la Sociedad Española de Reumatología Working Group. First signs and symptoms of spondyloarthritis. Data from an inception cohort with a disease course of two years of less (REGISPONSER-Early). Rheumatology 48 (2009) 404-409
56. Rosenbaum R.B. Neuromuscular complications of connective tissue diseases. Muscle Nerve 24 (2001) 154-169
57. Salaffi F., Stancati A., Neri R., Grassi W., and Bombardieri S. Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the recent-onset arthritis disability (ROAD) index. Clin Exp Rheumatol 23 5 Suppl. (2005) 31-42
58. Salih A.M., Nixon N.B., Dawes P.T., and Mattey D.L. Prevalence of antibodies to neurofilament polypeptides in patients with rheumatoid arthritis complicated by peripheral neuropathy. Clin Exp Rheumatol 16 (1998) 689-694
59. Salih A.M., Nixon N.B., Dawes P.T., and Mattey D.L. Antibodies to neuroblastoma cells in rheumatoid arthritis: a potential marker for neuropathy. Clin Exp Rheumatol 18 (2000) 23-30
60. Savolainen E., Kaipiainen-Seppanen O., Kroger L., and Luosujarvi R. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 30 (2003) 2460-2468
61. Schieir O., Thombs B.D., Hudson M., Taillefer S., Steele R., Berkson L., et al. Symptoms of depression predict the trajectory of pain among patients with early inflammatory arthritis: a path analysis approach to assessing change. J Rheumatol 36 (2009) 231-239
62. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 (2006) 704-712
63. Sheane B.J., Doyle F., Doyle C., O'Loughlin C., Howard D., and Cunnane G. Sub-optimal pain control in patients with rheumatic disease. Clin Rheumatol 27 (2008) 1029-1033
64. Sheppard J., Kumar K., Buckley C.D., Shaw K.L., and Raza K. 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis. Rheumatology 47 (2008) 1577-1582
65. Smedstad L.M., Moum T., Vaglum P., and Kvien T.K. The impact of early rheumatoid arthritis on psychological distress. A comparison between 238 patients with RA and 116 matched controls. Scand J Rheumatol 25 (1996) 377-382
66. Smolen J.S., Breedveld F.C., Schiff M.H., Kalden J.R., Emery P., Eberl G., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42 (2003) 244-257
67. Soderlin M.K., Borjesson O., Kautiainen H., Skogh T., and Leirisalo- Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 61 (2002) 911-915
68. Sokka T., Hannonen P., and Möttönen T. Conventional disease-modifying antirheumatic drugs in early arthritis. Rheum Dis Clin North Am 31 (2005) 729-744
69. Sprangers M.A., de Regt E.B., Andries F., van Agt H.M., Bijl R.V., de Boer J.B., et al. Which chronic conditions are associated with better or poorer quality of life?. J Clin Epidemiol 53 (2000) 895-907
70. Strand V., and Singh J.A. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 13 9 Suppl. (2007) 237-251
71. Strusberg I., Mendelberg R.C., Serra H.A., and Strusberg A.M. Influence of weather conditions on rheumatic pain. J Rheumatol 29 (2002) 335-338
72. Valesini G., Montecucco C., and Cutolo M. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24 (2006) 413-423
73. Van der Helm-van Mil A.H., Detert J., Le Cessie S., Filer A., Bastian H., Burmester G.R., et al. Validation of a prediction rule for disease outcome in patients with recent onset undifferentiated arthritis. Moving toward individualized treatment decision-making. Arthritis Rheum 58 (2008) 2241-2247
74. van Gestel A.M., Prevoo M.L., Van't Hof M.A., van Rijswijk M.H., van de Putte L.B., and van Riel P.L. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American college of rheumatology and the World Health Organization/international league against rheumatism criteria. Arthritis Rheum 39 (1996) 34-40
75. Wang X.M., Hamza M., Wu T.X., and Dionne R.A. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: correlation to clinical pain. Pain 142 (2009) 275-283
76. WHO. The burden of musculoskeletal conditions at the start of the millennium. World Health Organ Tech Rep Ser 919 (2003) 1-218
77. Zautra A.J., Parrish B.P., Van Puymbroeck C.M., Tennen H., Davis M.C., Reich J.W., et al. Depression history, stress, and pain in rheumatoid arthritis patients. J Behav Med 30 (2007) 187-197